BCL2A1 and breast carcinoma: In this study, we are the first to demonstrate gene expression profile screening for 6 different breast cancer cell lines with different molecular subtypes and show that BCL2A1 was only expressed after CHCP treatment in TNBC and silencing of BCL2A1 by siRNA or inhibit its expression by CPI203 increased the potency of CHCP treatment.